Company intelligence / Profile preview
Inhibitor Therapeutics, Inc.
Tampa, Florida, United Statesinhibitortx.com ↗
- Ownership
- Public · INTI
- Employees
- ~9
- Development stage
- Other
01
Overview
The company’s lead candidate SUBA-Itraconazole has completed a positive Phase 2b trial in basal cell carcinoma nevus syndrome. Itraconazole has shown activity against multiple tumor types and the company holds significant IP around its use in oncology. Other programs are at earlier stages targeting prostate and lung cancers using repurposed small molecules.
- Therapeutic areas
- OtherOncology
- Modalities
- Small molecules (repurposed drugs; specifically oral itraconazole)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johns Hopkins University (license agreement)
04
Financials
- Market cap
- $13.7M
- Total revenue
- $0
- Enterprise value
- $13.3M
Beyond the preview
Go deeper on Inhibitor Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibitor Therapeutics, Inc..